Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Current treatment standards for primary ovarian cancer

BGICC 2021

21 - 22 Jan 2021

Published: 18 Feb 2021

Views: 615

Rating:

Save

Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA

Prof Robert Coleman speaks to ecancer in an online interview for the virtual BGICC 2021 meeting about the current treatment standards for primary ovarian cancer.

He believes that in the last 6 years there has been a revolution in how we approach this disease due to the understanding of the BRCA mutations and how PARP inhibitors can demonstrate therapeutic efficacy.

Prof Coleman explains that this subsequently paved the way for more trials evaluating the use of more PARP inhibitors.

Related Videos

ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer

Prof Karim Fizazi, Dr Anders Bjartell, Dr Niven Mehra and Prof Eleni Efstathiou

ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer ( Prof Karim Fizazi, Dr Anders Bjartell, Dr Niven Mehra and Prof Eleni Efstathiou )

Hormonal receptor positive breast cancer adjuvant and metastatic indications

Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA

Hormonal receptor positive breast cancer adjuvant and metastatic indications ( Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA )

ASCO 2024: Lung cancer highlights

Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom

ASCO 2024: Lung cancer highlights ( Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom )

Trial argues strongly for the development of 1st-line biomarker selected strategies in pancreatic ductal adenocarcinoma

Prof Jennifer Knox - University of Toronto, Toronto, Canada

Trial argues strongly for the development of 1st-line biomarker selected strategies in pancreatic ductal adenocarcinoma ( Prof Jennifer Knox - University of Toronto, Toronto, Canada )

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer

Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City, USA

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer ( Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City, USA )

Choosing Wisely in pathology

Dr Angela Mlole - Ocean Road Cancer Institute, Dar es Salaam, Tanzania

Choosing Wisely in pathology ( Dr Angela Mlole - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )

Moving to the future: Artificial intelligence in surgery

Dr Maria João Cardoso - Champalimaud Cancer Centre, Lisbon, Portugal

Moving to the future: Artificial intelligence in surgery ( Dr Maria João Cardoso - Champalimaud Cancer Centre, Lisbon, Portugal )

More from ecancer